CD274 and neoplasm: Furthermore, when anti-PD-L1 therapy is used in combination with vMYX-hTNF the two modalities can act together to treat established tumors (as defined by threshold criteria of tumor cell luciferase expression levels of 5 × 105 luminescence units in the lung) at treatment start times, under conditions where both of the monotherapies were shown to be ineffective.